Viol Medical has signed an additional supply agreement for its microneedle RF device Syfill X with Chinese partner Sihuan Pharmaceutical, aiming to accelerate growth in China's medical aesthetics market. The deal, sealed at a strategy ceremony in Beijing on May 28, 2026, underscores rising demand for energy-based aesthetic devices in China and offers overseas suppliers a window into partnership dynamics in this key market.
Deal details
Viol Medical and Sihuan Pharmaceutical held the "Syfill X 2026 Strategy Ceremony" in Beijing on May 28, 2026. Senior representatives from both companies signed the additional supply contract and discussed future collaboration. The partners shared business performance data and core product portfolios, and explored ways to expand cooperation across marketing, academic support for clinicians, and supply.
Market signal
Syfill X sales in China grew 139% year-on-year in 2025, according to Viol Medical. The company attributes the surge to rising local demand, aggressive marketing, and academic activities. China remains one of the fastest-growing medical aesthetics markets in Asia, and this partnership signals sustained momentum for energy-based devices.
Partnership background
Sihuan Pharmaceutical has been the exclusive distributor of Syfill X in China since 2022. The two companies have steadily expanded the brand's presence in the region. The latest agreement is expected to further accelerate market penetration, leveraging Sihuan's local distribution network and Viol Medical's device technology.
Product context
Syfill X is Viol Medical's flagship microneedle RF device, used for scar reduction, pore refinement, pigmentation, and vascular improvement. Its precision energy delivery technology has attracted interest from clinicians both in South Korea and abroad. The device is positioned as a key tool in non-invasive aesthetic treatments.
What buyers should watch
For overseas importers and distributors, this deal highlights the importance of strong local partnerships in China's regulated medical aesthetics market. Viol Medical's 139% sales jump in 2025 suggests robust end-user demand for microneedle RF technology. Buyers evaluating similar devices should monitor regulatory pathways, distributor capabilities, and clinical support programs as critical success factors.
Source: Read the original report | Published: June 05, 2026